New: the Income Securities Screening Form now screens by price, yield, S&P rating, call status and trading volume, and you can save your searches to run again. Try the updated form.
GRI Bio, Inc. (GRI)
GRI · NCM · Common · CUSIP 3622AW106
Last Price•••.••
Current Yield•.••%
Yield to Call•.••%
Yield to Worst•.••%
Free registration unlocks the quote, yield calculations, price chart and full fundamentals for GRI and every other security on QuantumOnline.
🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type
Common Stock
CUSIP
3622AW106 (prev. 92023M101 )
IPO
2/10/2021 · 2.25 Million Shares @ $8.00/share
Prospectus
IPO prospectus »
Previous Symbol
VLON (changed 4/24/2023)
Previous Name
Vallon Pharmaceuticals Inc.
Business: GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis.

Company Contact

CEO
Marc Hertz
CFO
Leanne Kelly
Headquarters
2223 Avenida de la Playa, #208, La Jolla, CA 92037
Phone
267-607-8255
Investor Relations
Jenene Thomas, JTC Team · 833-475-8247 · GRI@jtcir.com
Email Form
Contact Form »
SEC EDGAR Filings
View filings »